Drugs / ASLAN004
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04090229 | Sep 2019 → Oct 2021 | atopic eczema | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03721263 | Oct 2018 → Mar 2019 | allergic disease | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05158023 | Mar 2022 → Jun 2023 | atopic eczema | ASLAN Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASLAN004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05158023 ↗ |
| Known as | Eblasakimab | “Eblasakimab, a first-in-class monoclonal antibody with a unique mechanism to target the interleukin (IL)-13 receptor alpha 1 (IL-13Rα1), inhibits IL-4/IL-13 signaling in the...” PMID 39404994 ↗ Oct 2024 |
| Action | Inhibit | “inhibits IL-4/IL-13 signaling in the pathophysiology of atopic dermatitis (AD).” PMID 39404994 ↗ Oct 2024 |
| Modality | Monoclonal antibody | “Eblasakimab, a first-in-class monoclonal antibody” PMID 39404994 ↗ Oct 2024 |
| Route | Intravenous | “using intravenous (IV) administration of ASLAN004” NCT03721263 ↗ |
| Target | IL13RA1 | “target the interleukin (IL)-13 receptor alpha 1 (IL-13Rα1)” PMID 39404994 ↗ Oct 2024 |